<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        146-186-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SARF 750MG TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        72.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Sarf</strong> contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria.</p><p><strong><u>Adults </u></strong></p><p><strong>Sarf</strong> is used in adults to treat the following bacterial infections:</p><p>-&nbsp; Respiratory tract infections</p><p>-&nbsp; Long lasting or recurring ear or sinus infections</p><p>-&nbsp; Urinary tract infections</p><p>-&nbsp; Genital tract infections in men and women</p><p>-&nbsp; Gastro-intestinal tract infections and intra-abdominal infections</p><p>-&nbsp; Skin and soft tissue infections</p><p>-&nbsp; Bone and joint infections</p><p>-&nbsp; To prevent infections due to the bacterium <em>Neisseria meningitidis </em></p><p>-&nbsp; Anthrax inhalation exposure</p><p>Ciprofloxacin may be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be due to a bacterial infection.</p><p>If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to <strong>Sarf</strong>.</p><p><strong><u>Children and adolescents </u></strong></p><p><strong>Sarf</strong> is used in children and adolescents, under specialist medical supervision, to treat the following bacterial infections:</p><p>-&nbsp; Lung and bronchial infections in children and adolescents suffering from cystic fibrosis</p><p>-&nbsp; Complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis)</p><p>-&nbsp; Anthrax inhalation exposure</p><p><strong>Sarf</strong> may also be used to treat other specific severe infections in children and adolescents when your doctor considered this necessary</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Sarf: </strong></p><p>-&nbsp; If you are allergic to the active substance, to other quinolone drugs or to any of the other ingredients of this medicine (listed in Section 6)</p><p>-&nbsp; If you are taking tizanidine (see Section 2: Other medicines and <strong>Sarf</strong>)</p><p><strong>Warnings and precautions </strong></p><p><strong>Talk to your doctor before taking Sarf </strong></p><p>-&nbsp; If you have ever had kidney problems because your treatment may need to be adjusted.</p><p>-&nbsp; If you suffer from epilepsy or other neurological conditions.</p><p>-&nbsp; If you have a history of tendon problems during previous treatment with antibiotics such as <strong>Sarf</strong>.</p><p>-&nbsp; If you are diabetic because you may experience a risk of hypoglycaemia with ciprofloxacin.</p><p>-&nbsp; If you have myasthenia gravis (a type of muscle weakness) because symptoms can be exacerbated.</p><p>-&nbsp; If you have heart problems. Caution should be taken when using Ciprofloxacin, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section 2: Other medicines and <strong>Sarf</strong>).</p><p>-&nbsp; If you or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase (G6PD), since you may experience a risk of anaemia with ciprofloxacin.</p><p>For the treatment of some genital tract infections, your doctor can prescribe another antibiotic in addition to ciprofloxacin. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.</p><p><strong>While taking Sarf </strong></p><p>Tell your doctor immediately, if any of the following occurs <strong>while taking Sarf</strong>. Your doctor will decide whether treatment with <strong>Sarf</strong> needs to be stopped.</p><p>-&nbsp; <strong>Severe, sudden allergic reaction </strong>(an anaphylactic reaction/shock, angio-oedema). Even with the first dose, there is a small chance that you may experience a severe allergic reaction with the following symptoms: tightness in the chest, feeling dizzy, sick or faint, or experiencing dizziness when standing up. <strong>If this happens, stop taking Sarf and contact your doctor immediately. </strong></p><p>-&nbsp; <strong>Pain and swelling in the joints and tendinitis </strong>may occur occasionally, particularly if you are elderly and are also being treated with corticosteroids. Inflammation and ruptures of tendons may occur even within the first 48 hours of treatment or up to several months after discontinuation of <strong>Sarf</strong> therapy. At the first sign of any pain or inflammation stop taking <strong>Sarf</strong> and rest the painful area. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture.</p><p>-&nbsp; If you suffer from <strong>epilepsy </strong>or other <strong>neurological conditions </strong>such as cerebral ischemia or stroke, you may experience side effects associated with the central nervous system. If this happens, stop taking <strong>Sarf</strong> and contact your doctor immediately.</p><p>-&nbsp; You may experience <strong>psychiatric reactions </strong>the first time you take <strong>Sarf</strong>. If you suffer from <strong>depression </strong>or <strong>psychosis</strong>, your symptoms may become worse under treatment with <strong>Sarf</strong>. In rare cases, depression or psychosis can progress to thoughts of suicide, suicide attempts, or completed suicide. If this happens, stop taking <strong>Sarf</strong> and contact your doctor immediately.</p><p>-&nbsp; You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or weakness. If this happens, stop taking <strong>Sarf</strong> and contact your doctor immediately.</p><p>-&nbsp; <strong>Hypoglycemia </strong>has been reported most often in diabetic patients, predominantly in elderly population. If this happens, contact your doctor immediately.</p><p>-&nbsp; <strong>Diarrhoea </strong>may develop while you are taking antibiotics, including <strong>Sarf</strong>, or even several weeks after you have stopped taking them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, stop taking <strong>Sarf</strong> immediately, as this can be life-threatening. Do not take medicines that stop or slow down bowel movements and contact your doctor.</p><p>-&nbsp; If your <strong>eyesight becomes impaired</strong> or if your eyes seems to be otherwise affected, consult an eye specialist immediately<strong>.</strong></p><p>-&nbsp; Tell the doctor or laboratory staff that you are taking <strong>Sarf</strong> if you have to provide a <strong>blood or urine sample</strong>.</p><p>-&nbsp; If you suffer from <strong>kidney problems</strong>, tell the doctor because your dose may need to be adjusted.</p><p>-&nbsp; <strong>Sarf</strong> may cause <strong>liver damage</strong>. If you notice any symptoms such as loss of appetite, jaundice (yellowing of the skin), dark urine, itching, or tenderness of the stomach, stop taking <strong>Sarf</strong> and contact your doctor immediately.</p><p>-&nbsp; <strong>Sarf</strong> may cause a reduction in the number of white blood cells and your <strong>resistance to infection may be decreased</strong>. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your medicine.</p><p>-&nbsp; Your skin becomes more <strong>sensitive to sunlight or ultraviolet (UV) light </strong>when taking <strong>Sarf</strong>. Avoid exposure to strong sunlight, or artificial UV light such as sunbeds.</p><p><strong>Other medicines and Sarf </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>Do not take Sarf together with tizanidine</strong>, because this may cause side effects such as low blood pressure and sleepiness (see Section 2: Do not take <strong>Sarf</strong>).</p><p>The following medicines are known to interact with <strong>Sarf</strong> in your body. Taking <strong>Sarf</strong> together with these medicines can influence the therapeutic effect of those medicines. It can also increase the probability of experiencing side effects.</p><p><strong>Tell your doctor if you are taking</strong>:</p><p>-&nbsp; Vitamin K antagonists (e.g. warfarin, acenocoumarol, phenprocoumon or fluindione) or other oral anti-coagulants (to thin the blood)</p><p>-&nbsp; Probenecid (for gout)</p><p>-&nbsp; Methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis)</p><p>-&nbsp; Theophylline (for breathing problems)</p><p>-&nbsp; Tizanidine (for muscle spasticity in multiple sclerosis)</p><p>-&nbsp; Olanzapine (an antipsychotic)</p><p>-&nbsp; Clozapine (an antipsychotic)</p><p>-&nbsp; Ropinirole (for Parkinson&rsquo;s disease)</p><p>-&nbsp; Phenytoin (for epilepsy)</p><p>-&nbsp; Metoclopramide (for nausea and vomiting)</p><p>-&nbsp; Cyclosporin (for skin conditions, rheumatoid arthritis and in organ transplantation)</p><p>-&nbsp; Other medicines that can alter your heart rhythm: medicines that belong to the group of anti arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics.</p><p>-&nbsp; Zolpidem (for sleep disorder).</p><p><strong>Sarf</strong> may <strong>increase </strong>the levels of the following medicines in your blood:</p><p>-&nbsp; Pentoxifylline (for circulatory disorders)</p><p>-&nbsp; Caffeine</p><p>-&nbsp; Duloxetine (for depression, diabetic nerve damage or incontinence)</p><p>-&nbsp; Lidocaine (for heart conditions or anaesthetic use)</p><p>-&nbsp; Sildenafil (e.g. for erectile dysfunction)</p><p>-&nbsp; Agomelatine (for depression)</p><p>Some medicines <strong>reduce </strong>the effect of <strong>Sarf</strong>. Tell your doctor if you take or wish to take:</p><p>-&nbsp; Antacids</p><p>-&nbsp; Omeprazole</p><p>-&nbsp; Mineral supplements</p><p>-&nbsp; Sucralfate</p><p>-&nbsp; A polymeric phosphate binder (e.g. sevelamer or lanthanum carbonate)</p><p>-&nbsp; Medicines or supplements containing calcium, magnesium, aluminium or iron</p><p>If these preparations are essential, take <strong>Sarf</strong> about two hours before or no sooner than four hours after them.</p><p><strong>Sarf with food and drink </strong></p><p>Unless you take <strong>Sarf</strong> during meals, do not eat or drink any dairy products (such as milk or yoghurt) or drinks with added calcium when you take the tablets, as they may affect the absorption of the active substance.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>It is preferable to avoid the use of <strong>Sarf</strong> during pregnancy.</p><p>Do not take <strong>Sarf</strong> during breast-feeding because ciprofloxacin is excreted in breast milk and can be harmful for your child.</p><p><strong>Driving and using machines </strong></p><p><strong>Sarf</strong> may make you feel less alert. Some neurological adverse events can occur. Therefore, make sure you know how you react to <strong>Sarf</strong> before driving a vehicle or operating machinery. If in doubt, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will explain to you exactly how much <strong>Sarf</strong> you will have to take as well as how often and for how long. This will depend on the type of infection you have and how bad it is.</p><p>Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.</p><p>The treatment usually lasts from 5 to 21 days, but may take longer for severe infections. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure how many tablets to take and how to take <strong>Sarf</strong>.</p><p>&middot;&nbsp; Swallow the tablets with plenty of fluid. Do not chew the tablets because they do not taste nice.</p><p>&middot;&nbsp; Do try to take the tablets at around the same time every day.</p><p>&middot;&nbsp; You can take the tablets at mealtimes or between meals. Any calcium you take as part of a meal will not seriously affect uptake. However, <strong>do not </strong>take <strong>Sarf</strong> tablets with dairy products such as milk or yoghurt or with fortified fruit juices (e.g. calcium-fortified orange juice).</p><p>Remember to drink plenty of fluids while you are taking this medicine.</p><p><strong>If you take more Sarf than you should </strong></p><p>If you take more than the prescribed dose, get medical help immediately. If possible, take your tablets or the box with you to show the doctor.</p><p><strong>If you forget to take Sarf </strong></p><p>Take the normal dose as soon as possible and then continue as prescribed. However, if it is almost time for your next dose, do not take the missed dose and continue as usual. Do not take a double dose to make up for a forgotten dose. Be sure to complete your course of treatment.</p><p><strong>If you stop taking Sarf </strong></p><p>It is important that you <strong>finish the course of treatment </strong>even if you begin to feel better after a few days. If you stop taking this medicine too soon, your infection may not be completely cured and the symptoms of the infection may return or get worse. You might also develop resistance to the antibiotic.</p><p>If you have any further questions about the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Common: </strong></p><p>May affect up to 1 in 10 people</p><p>-&nbsp; Nausea, diarrhoea</p><p>-&nbsp; Joint pains in children</p><p><strong>Uncommon: </strong></p><p>May affect up to 1 in 100 people</p><p>-&nbsp; Fungal superinfections</p><p>-&nbsp; A high concentration of eosinophils, a type of white blood cell</p><p>-&nbsp; Decreased appetite</p><p>-&nbsp; Hyperactivity or agitation</p><p>-&nbsp; Headache, dizziness, sleeping problems, or taste disorders</p><p>-&nbsp; Vomiting, abdominal pain, digestive problems such as stomach upset (indigestion/heartburn), or wind</p><p>-&nbsp; Increased amounts of certain substances in the blood (transaminases and/or bilirubin)</p><p>-&nbsp; Rash, itching, or hives</p><p>-&nbsp; Joint pain in adults</p><p>-&nbsp; Poor kidney function</p><p>-&nbsp; Pains in your muscles and bones, feeling unwell (asthenia), or fever</p><p>-&nbsp; Increase in blood alkaline phosphatase (a certain substance in the blood)</p><p><strong>Rare: </strong></p><p>May affect up to 1 in 1,000 people</p><p>-&nbsp; Inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases) (see Section 2: Warnings and precautions)</p><p>-&nbsp; Changes to the blood count (leukopenia, leukocytosis, neutropenia, anaemia), increased or decreased amounts of a blood clotting factor (thrombocytes)</p><p>-&nbsp; Allergic reaction, swelling (oedema), or rapid swelling of the skin and mucous membranes (angio-oedema)</p><p>-&nbsp; Increased blood sugar (hyperglycaemia)</p><p>-&nbsp; Decreased blood sugar (hypoglycaemia) (see Section 2: Warnings and precautions)</p><p>-&nbsp; Confusion, disorientation, anxiety reactions, strange dreams, depression (potentially leading to thoughts of suicide, suicide attempts, or completed suicide), or hallucinations</p><p>-&nbsp; Pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors, seizures (see Section 2: Warnings and precautions), or giddiness</p><p>-&nbsp; Eyesight problems including double vision</p><p>-&nbsp; Tinnitus, loss of hearing, impaired hearing</p><p>-&nbsp; Rapid heartbeat (tachycardia)</p><p>-&nbsp; Expansion of blood vessels (vasodilation), low blood pressure, or fainting</p><p>-&nbsp; Shortness of breath, including asthmatic symptoms</p><p>-&nbsp; Liver disorders, jaundice (cholestatic icterus), or hepatitis</p><p>-&nbsp; Sensitivity to light (see Section 2: Warnings and precautions)</p><p>-&nbsp; Muscle pain, inflammation of the joints, increased muscle tone, or cramp</p><p>-&nbsp; Kidney failure, blood or crystals in the urine (see Section 2: Warnings and precautions), urinary tract inflammation</p><p>-&nbsp; Fluid retention or excessive sweating</p><p>-&nbsp; Increased levels of the enzyme amylase</p><p><strong>Very rare: </strong></p><p>May affect up to 1 in 10,000 people</p><p>-&nbsp; A special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of white blood cells (agranulocytosis); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal (see Section 2: Warnings and precautions)</p><p>-&nbsp; Severe allergic reactions (anaphylactic reaction or anaphylactic shock, which can be fatal - serum sickness) (see Section 2: Warnings and precautions)</p><p>-&nbsp; Mental disturbances (psychotic reactions potentially leading to thoughts of suicide, suicide attempts, or completed suicide) (see Section 2: Warnings and precautions)</p><p>-&nbsp; Migraine, disturbed coordination, unsteady walk (gait disturbance), disorder of sense of smell (olfactory disorders), pressure on the brain (intracranial pressure and pseudotumor cerebri)</p><p>-&nbsp; Visual colour distortions</p><p>-&nbsp; Inflammation of the wall of the blood vessels (vasculitis)</p><p>-&nbsp; Pancreatitis</p><p>-&nbsp; Death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure</p><p>-&nbsp; Small, pin-point bleeding under the skin (petechiae); various skin eruptions or rashes (for example, the potentially fatal Stevens-Johnson syndrome or toxic epidermal necrolysis)</p><p>-&nbsp; Muscle weakness, tendon inflammation, tendon rupture &ndash; especially of the large tendon at the back of the ankle (Achilles tendon) (see Section 2: Warnings and precautions); worsening of the symptoms of myasthenia gravis (see Section 2: Warnings and precautions)</p><p><strong>Not known: </strong></p><p>Frequency cannot be estimated from the available data.</p><p>-&nbsp; Feeling highly excited (mania) or feeling optimism and overactivity (hypomania).</p><p>-&nbsp; Troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities (peripheral neuropathy and polyneuropathy)</p><p>-&nbsp; Abnormal fast heart rhythm, life-threatening irregular heart rhythm, alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart)</p><p>-&nbsp; Pustular rash</p><p>-&nbsp; Hypersensetivity reaction called DRESS (Drug Reaction With Eosinphilia and Systemic Symptoms).</p><p>-&nbsp; Influence on blood clotting (in patients treated with Vitamin K antagonists)</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p><p>&nbsp;</p><p><strong><u>To report any side effect(s): </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax: </strong>+966-11-205-7662</p><p><strong>Call NPC </strong>at +966-11-2038222,</p><p><strong>Exts: </strong>2317-2356-2353-2354-2334-2340<strong>.</strong></p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>Website: </strong>www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and on the blister.</p><p>&middot;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp; Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and on the blister.</p><p>&middot;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp; Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The active substance is Ciprofloxacin. Each film-coated tablet contains 250mg, 500mg, or 750mg of Ciprofloxacin (as Hydrochloride).
The other ingredients: Sodium starch glycolate, crospovidone, microcrystalline cellulose, magnesium stearate, ethanol 96%, hypromellose, polyethylene glycol, and titanium dioxide.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                15/09/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي <strong>سارف</strong> على سيبروفلوكساسين كمادة فعالة. سيبروفلوكساسين هو مضاد حيوي ينتمي إلى مجموعة الفلوروكونيولون. يعمل سيبروفلوكساسين عن طريق قتل البكتيريا التي تسبب العدوى. إن سيبروفلوكساسين فعال فقط مع سلالات معينة من البكتيريا.</p><p><strong><u>البالغون</u></strong></p><p>يستخدم <strong>سارف </strong>لدى البالغين لعلاج حالات العدوى البكتيرية التالية:</p><p>-&nbsp; عدوى الجهاز التنفسي.</p><p>-&nbsp; عدوى طويلة الأمد أو متكررة في الأذن أو الجيوب الأنفية</p><p>-&nbsp; عدوى الجهاز البولي</p><p>-&nbsp; عدوى الجهاز التناسلي لدى الرجال والنساء</p><p>-&nbsp; عدوى الجهاز الهضمي وعدوى داخل البطن</p><p>-&nbsp; عدوى الجلد والنسيج الرخو</p><p>-&nbsp; عدوى العظام والمفاصل</p><p>-&nbsp; لمنع العدوى الناجمة عن بكتيريا النيسرية السحائية</p><p>-&nbsp; التعرض لاستنشاق الجمرة الخبيثة</p><p>قد يستخدم أيضاً سيبروفلوكساسين للسيطرة على المرضى الذين يعانون من انخفاض تعداد خلايا الدم البيضاء (قلة العدلات) والمصابون بالحمى والتي من المتوقع أن تكون ناجمة عن عدوى بكتيرية.</p><p>إذا كنت تعاني من عدوى شديدة أو من العدوى الناجمة عن أكثر من نوع واحد من البكتيريا، قد يعطى لك مضادات حيوية إضافية بالتزامن مع <strong>سارف</strong>.</p><p><strong><u>الأطفال والمراهقون</u></strong></p><p>يستخدم <strong>سارف </strong>لدى الأطفال والمراهقين، تحت إشراف طبي متخصص، لعلاج العدوى البكتيرية التالية:</p><p>-&nbsp; عدوى الرئة والشعب الهوائية لدى الأطفال والمراهقين الذين يعانون من تليف كيسي.</p><p>-&nbsp; عدوى الجهاز البولي المعقدة، بما في ذلك العدوى التي وصلت للكليتين (التهاب الحويضة والكلية).</p><p>-&nbsp; التعرض لاستنشاق الجمرة الخبيثة.</p><p>قد يستخدم <strong>سارف </strong>أيضاً لعلاج عدوى شديدة محددة أخرى لدى الأطفال والمراهقين عندما يعتبر طبيبك المعالج ذلك أمراً ضرورياً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عليك عدم تناول سارف في الحالات التالية:</strong></p><p>-&nbsp; &nbsp;&nbsp;إذا كنت تعاني من حساسية تجاه المادة الفعالة، أو تجاه أدوية أخرى من مجموعة الكوينولون أو أي من المواد الغير فعالة الأخرى التي يحتوي عليها هذا الدواء (المذكورة في قسم 6).</p><p>-&nbsp; إذا كنت تتناول تيزانيدين (انظرقسم 2: تناول الأدوية الأخرى مع <strong>سارف</strong>)</p><p><strong>تحذيرات واحتياطات:</strong></p><p><strong>يرجى منك التحدث إلى طبيبك المعالج قبل تناول سارف</strong></p><p>-&nbsp; إذا عانيت مسبقاً من مشاكل في الكلى لأنه قد تكون بحاجة إلى تعديل العلاج الخاص بك.</p><p>-&nbsp; إذا كنت تعاني من الصرع أو أية حالات عصبية أخرى.</p><p>-&nbsp; إذا كان لديك تاريخ مسبق من الإصابة بمشاكل في الوتر خلال فترة علاج سابق مع المضادات الحيوية على سبيل المثال <strong>سارف</strong>.</p><p>-&nbsp; إذا كنت تعاني من من داء السكري لأنه قد تتعرض لخطر المعاناة من نقص السكر مع تناول سيبروفلوكساسين.</p><p>-&nbsp; إذا كنت تعاني من الوهن العضلي الوبيل (نوع من أنواع ضعف في العضلات) لأن قد تزيد من حدة الأعراض الجانبية.</p><p>-&nbsp; إذا كنت تعاني من مشاكل في القلب. يرجى توخي الحذر عند تناول سيبروفلوكساسين، إذا كنت قد ولدت أو لديك تاريخ مسبق مع المعاناة من إطالة فترة كيو تي (التي تظهر في تخطيط كهربائية القلب، تسجيل كهربائي للقلب)، تعاني من اضطراب الأملاح في الدم (وبصفة خاصة انخفاض مستويات البوتاسيوم أو المغنيسيوم في الدم)، تعاني من ضربات قلب بطيئة جداً (تعرف باسم بطء القلب)، تعاني من ضعف في القلب (فشل القلب)، لديك تاريخ مرضي من الإصابة بالنوبة القلبية (انسداد العضلة القلبية)،كنت أنثى أو من فئة كبار السن أو كنت تتناول الأدوية الأخرى التي تؤدي إلى تغيرات غير طبيعية في تخطيط كهربائية القلب (انظر قسم 2: تناول الأدوية الأخرى مع<strong> سارف</strong>).</p><p>-&nbsp; إذا كان معروفاً لديك أنك أو أحد أفراد عائلتك يعاني من نقص في سداسي فوسفات الجلوكوز، وذلك لأنك قد تكون أكثر عرضة لخطر حدوث الإصابة بفقر الدم مع تناول سيبروفلوكساسين.</p><p>كما يمكن لطبيبك المعالج من وصف مضاد حيوي آخر بالتزامن مع سيبروفلوكساسين، لعلاج بعض عدوى جهاز التناسلي. يرجى منك استشارة طبيبك المعالج، مالم لم يكن هناك أي تحسن في الأعراض بعد 3 أيام من العلاج.</p><p><strong>أثناء تناول </strong><strong>سارف</strong></p><p>يرجى منك اخبار طبيبك المعالج على الفور، إذا حدث أياً مما يلي أثناء تناول <strong>سارف</strong>.</p><p>سوف يقرر طبيبك المعالج ما إذا كنت بحاجة إلى العلاج بدواء<strong> سارف.</strong></p><p><strong>-&nbsp; </strong><strong>تفاعلات تحسسية شديدة مفاجئة</strong> (هي تفاعلات استهدافية/الصدمة، وذمة وعائية). حتى مع تناول الجرعة الأولى، هناك فرصة ضئيلة بأنك قد تتعرض لتفاعلات تحسسية شديدة مصحوبة &nbsp;بالأعراض التالية: ضيق في الصدر، شعور بالدوار، إعياء أو إغماء، أو المعاناة من الدوخة عند الوقوف. <strong>إذا حدث ذلك،</strong> <strong>توقف عن تناول سارف واتصل بطبيبك المعالج على الفور.</strong></p><p>-&nbsp; قد يحدث <strong>ألم وتورم في المفاصل والأوتار</strong> في بعض الأحيان، وبصفة خاصة إذا كنت من فئة كبار السن وأيضاً سوف يتم علاجك بالأدوية الستيرويدية. &nbsp;قد يحدث التهاب وتمزق الأوتار في خلال 48 ساعة الأولى من العلاج أو ما يصل إلى عدة أشهر بعد التوقف عن علاج <strong>سارف</strong>. توقف عن تناول <strong>سارف</strong> عند ظهور أول علامة من الألم أو الالتهاب و يرجى منك عدم اجهاد منطقة الألم. تجنب أي ممارسة تمارين رياضية غير ضرورية، لأن ذلك قد يزيد من خطر حدوث تمزق الوتر.</p><p>-&nbsp; إذا كنت تعاني من <strong>الصرع</strong> أو <strong>حالات مرضية عصبية</strong> أخرى على سبيل المثال نقص التروية أو السكتة الدماغية، قد تتعرض لتأثيرات جانبية مرتبطة بالجهاز العصبي المركزي. توقف عن تناول <strong>سارف </strong>و تواصل مع طبيبك المعالج على الفور، إذا حدث ذلك.</p><p>-&nbsp; قد تعاني من <strong>تفاعلات نفسية</strong> عند تناول <strong>سارف </strong>لأول مرة. إذا عانيت من <strong>الاكتئاب</strong> أو <strong>الذهان</strong>، قد تتدهور الأعراض خلال العلاج مع <strong>سارف</strong>. في حالات نادرة، يمكن أن يتطور الاكتئاب أو الذهان إلى أفكار انتحارية، محاولات انتحارية، أو محاولة انتحار كاملة. توقف عن تناول <strong>سارف </strong>وتواصل مع طبيبك المعالج على الفور، إذا حدث هذا.</p><p>-&nbsp; قد تتعرض لأعراض الاعتلال العصبي على سبيل المثال ألم، حرقة، وخز، خدر و/أو شعور بالضعف. توقف عن تناول <strong>سارف </strong>وتواصل مع طبيبك المعالج على الفور، إذا حدث هذا.</p><p>-&nbsp; تم تسجيل <strong>نقص سكر</strong> الدم غالباً لدى مرضى داء السكري، والغالبية منهم من فئة كبار السن. يرجة التواصل مع طبيبك المعالج على الفور، إذا حدث ذلك.</p><p>-&nbsp; قد يحدث <strong>إسهال</strong> أثناء تناولك المضادات الحيوية، بما في ذلك <strong>سارف</strong>، ولو بعد التوقف عن تناول الدواء بعدة أسابيع. يرجى منك التوقف عن تناول الدواء، إذا زادت حدة &nbsp;الاسهال أو استمرت أو لاحظت وجود دم أو مخاط في البراز، لأن ذلك يمكن أن يكون مهدداً للحياة. يجب عدم تناول الأدوية التي تعمل على توقف أو تباطؤ حركة الأمعاء ويرجى منك الواصل مع طبيبك المعالج.</p><p>-&nbsp; يرجى منك استشارة أخصائي العيون على الفور، إذا تدهورت الرؤية لديك أو إذا تأثرت عينيك.</p><p>-&nbsp; يرجى منك اخبار طبيبك المعالج أو موظفين المختبر بأنك تتناول <strong>سارف</strong> إذا كان عليك تقديم عينة من <strong>الدم</strong> أ<strong>والبول</strong>.</p><p>-&nbsp; يرجى منك اخبار طبيبك المعالج، إذا كنت تعاني من <strong>مشاكل</strong> <strong>في</strong> <strong>الكلى</strong> لأنه قد تكون بحاجة لتعديل الجرعة الخاصة بك.</p><p>-&nbsp; قد يسبب <strong>سارف تلف</strong> <strong>الكبد</strong>. توقف عن تناول <strong>سارف </strong>وتواصل مع طبيبك المعالج على الفور، إذا لاحظت أي أعراض على سبيل المثال فقدان الشهية، يرقان (اصفرار الجلد) بول داكن، حكة، أو ألم في المعدة عند الضغط عليها.</p><p>-&nbsp; قد يسبب <strong>سارف </strong>انخفاض في تعداد خلايا الدم البيضاء <strong>وقد تقل</strong> <strong>مقاومتك</strong> <strong>للعدوى</strong>. يجب عليك مراجعة طبيبك المعالج على الفور، إذا عانيت من العدوى المصحوبة بأعراض على سبيل المثال حمى وتدهور خطير في الحالة العامة لك، أو حمى مصحوبة بأعراض العدوى الموضعية على سبيل المثال احتقان الحلق/البلعوم/الفم أو مشاكل في التبول. سوف يتم أخذ عينة دم لفحص احتمالية حدوث نقص في تعداد خلايا الدم البيضاء (نقص العدلات). من الضروري اخبار طبيبك المعالج بالدواء الذي تتناوله.</p><p>-&nbsp; سوف يصبح جلدك أكثر تحسساً <strong>لأشعة الشمس أو الأشعة الفوق بنفسجية</strong> عند تناول <strong>سارف</strong>. تجنب التعرض لأشعة الشمس القوية، أو الأشعة الفوق ابنفسجية الاصطناعية على سبيل المثال الحمام الشمسي.</p><p><strong>تناول الأدوية الأخرى مع سارف</strong></p><p>يرجى منك اخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول، تناولت مؤخراً أو قد تناولت أية أدوية أخرى.</p><p><strong>يجب عليك عدم تناول سارف بالتزامن مع تيزانيدين</strong>، لأن ذلك قد يسبب تأثيرات جانبية على سبيل المثال انخفاض ضغط الدم و الشعور بالنعاس (انظر قسم 2: يجب عدم تناول<strong> سارف</strong>).</p><p>من المعروف أن الأدوية التالية تتفاعل مع <strong>سارف </strong>في جسمك. يمكن أن يؤثر تناول <strong>سارف </strong>بالتزامن مع هذه الأدوية على التأثير العلاجي لهذه الأدوية. و يمكن أيضاً أن تزيد من احتمالية التعرض لحدوث التأثيرات الجانبية.</p><p><strong>يرجى منك اخبار طبيبك المعالج إذا كنت تتناول:</strong></p><p>-&nbsp; مثبطات فيتامين ك (على سبيل المثال وارفارين، أسينوكومارول، فينوبروكومون أو فلوانديون) أو مضادات التخثر الأخرى (التي تعمل على ترقيق الدم)</p><p>-&nbsp; بروبنيسيد (لمرض النقرس)</p><p>-&nbsp; ميثوتريكسيت (لعلاج أنواع معينة من السرطان، الصدفية، والتهاب المفاصل الروماتويدي)</p><p>-&nbsp; ثيوفيلين (لعلاج مشاكل في التنفس)</p><p>-&nbsp; تيزانيدين (لعلاج تشنج العضلات في التصلب المتعدد)</p><p>-&nbsp; أولانزابين (أحد مضادات الذهان)</p><p>-&nbsp; كلوزابين (أحد مضادات الذهان)</p><p>-&nbsp; روبينيرول (لعلاج مرض باركنسون)</p><p>-&nbsp; فينيتوين (لعلاج مرض الصرع)</p><p>-&nbsp; ميتوكلوبراميد (لعلاج الغثيان والتقيؤ)</p><p>-&nbsp; سيكلوسبورين (لعلاج الحالات الجلدية المرضية، التهاب المفاصل الروماتويدي و في عمليات زرع الأعضاء)</p><p>-&nbsp; الأدوية الأخرى التي يمكن أن تغير نظم القلب: الأدوية التي تنتمي إلى مضادات اضطرات نظم القلب ( على سبيل المثال كينيدين، هيدروكينيدين، ديسوبيراميد اميودارون، السوتالول، دوفيتيلايد، آيبوتيلايد)، مضادات الاكتئاب ثلاثي الحلقات، وبعض مضادات الميكروبي (التي تنتمي إلى مجموعة الماكروليدات)، بعض مضادات الذهان.</p><p>-&nbsp; زولبيديم (لعلاج اضطرابات النوم).</p><p>قد <strong>يزيد</strong> <strong>سارف</strong> من مستويات الأدوية التالية في الدم:</p><p>-&nbsp; البنتوكسيفيلين (لعلاج اضطرابات الدورة الدموية)</p><p>-&nbsp; الكافيين</p><p>-&nbsp; دولوكستين (لعلاج الاكتئاب، تلف الأعصاب السكري أو سلس البول)</p><p>-&nbsp; ليدوكايين (لعلاج أمراض القلب أو استخدامه كمخدر)</p><p>-&nbsp; سيلدينافيل (يستخدم على سبيل المثال لعلاج عدم القدرة على الانتصاب)</p><p>قد <strong>تقلل </strong>بعض الأدوية من تأثير عمل <strong>سارف</strong>. يرجى منك اخبار طبيبك المعالج إذا كنت تتناول أو ترغب بتناول الأدوية التالية:</p><p>-&nbsp; مضادات الحموضة</p><p>-&nbsp; أوميبرازول</p><p>-&nbsp; مكملات المعادن</p><p>-&nbsp; سوكرالفات</p><p>-&nbsp; مركب رابطات الفوسفات (على سبيل المثال سيفيلامير أو كربونات اللانثانوم)</p><p>-&nbsp; الأدوية أو المكملات الغذائية التي تحتوي على الكالسيوم، المغنيسيوم، الألمنيوم أو الحديد.</p><p>إذا كا ن تناول هذه الأدوية ضرورياً، تناول <strong>سارف</strong> بحوالي ساعتين قبل أو في موعد لا يتجاوز الأربع ساعات من بعد تناول هذه الأدوية.</p><p><strong>سارف مع الطعام والشراب</strong></p><p>في حال عدم تناول <strong>سارف </strong>أثناء وجبات الطعام، يجب عدم&nbsp; أكل أو شرب أياً من منتجات الألبان (على سبيل المثال الحليب و اللبن والرائب) أو المشروبات المضاف إليها الكالسيوم عندما تتناول أقراصك، حيث أنها قد تؤثر على امتصاص المادة الفعالة.&nbsp;</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعاملين معه للحصول على النصيحة قبل تناول هذا الدواء، إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين أنك حاملاً أو تخططين لإنجاب طفلاً.</p><p>من الأفضل تجنب تناول <strong>سارف </strong>خلال فترة الحمل.</p><p>يجب عدم تناول <strong>سارف </strong>في فترة الرضاعة الطبيعية لأن سيبروفلوكساسين يفرز في حليب الثدي و يمكن أن تكون ضارة لطفلك.</p><p><strong>القيادة واستخدام الآلات</strong></p><p>قد يجعلك <strong>سارف </strong>تشعر بقلة التركيز. يمكن أن تحدث بعض الأعراض العصبية العكسية. لذلك، تأكد من معرفة كيفية استجابتك <strong>لسارف </strong>قبل قيادة المركبات أو تشغيل الآلات. يرجى منك استشارة طبيبك المعالج، إذا راودك أي شك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يشرح لك طبيبك المعالج بدقة عن الكمية التي يجب عليك تناولها من <strong>سارف </strong>وكذلك عن عدد المرات و المدة اللازمة لتناوله. سوف يعتمد هذا على نوع العدوى التي تعاني منها و مدى حدتها.</p><p>يرجى منك اخبار طبيبك المعالج إذا كنت تعاني من مشاكل في الكلى لأنك قد تكون بحاجة لتعديل الجرعة الخاصة بك.</p><p>يستمر العلاج عادة من 5 إلى 21 يوم، ولكن قد يستغرق وقتا أطول لعلاج الالتهابات الشديدة. احرص دائماً على تناول الأقراص الخاصة بك بدقة وفقاً لتعليمات طبيبك المعالج . يرجى منك استشارة الطبيب المعالج أو الصيدلي الذي تتعامل معه مالم تكن متأكداً من عدد الأقراص التي يجب تناولها أو كيفية تناول <strong>سارف</strong>.</p><p>&middot;&nbsp; قم بابتلاع &nbsp;الأقراص مع الكثير من السوائل. لا تقم بمضغ الأقراص وذلك لكون طعمها غير مستساغ.</p><p>&middot;&nbsp; حاول تناول الأقراص في نفس الوقت يومياً.</p><p>&middot;&nbsp; يمكنك أن تتناول الأقراص في أوقات الوجبات أو بين الوجباب. إن تناول أي كمية من الكالسيوم كجزء من الوجبة لن تؤثر على امتصاص بشكل خطير. ومع ذلك، لا تتناول <strong>سارف</strong> مع منتجات الألبان على سبيل المثال الحليب أو مع عصائر الفواكه المضاف إليها الكالسيوم (على سبيل المثال عصير البرتقال المدعم بالكالسيوم).</p><p>تذكر أن تشرب الكثير من السوائل أثناء تناولك هذا الدواء.</p><p><strong>إذا تناولت </strong><strong>سارف</strong><strong> بجرعة أكبر مما يجب </strong></p><p>إذا تناولت <strong>سارف</strong> بجرعة تزيد عن الجرعة الموصى بها، يرجى منك طلب المساعدة الطبية على الفور. خذ معك أقراصك أو العبوة&nbsp; لكي يراه الطبيب المعالج، إذا أمكن.</p><p><strong>إذا سهوت عن تناول سارف</strong></p><p>تناول الجرعة الاعتيادية في أسرع وقت ممكن ومن ثم الاستمرار كما هو موصى.</p><p>ومع ذلك، إذا حان وقت تناول الجرعة التالية تقريباً، لا تتناول الجرعة التي سهوت عنها &nbsp;والاستمرار كما هو معتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة المفردة التي قد سهوت عن تناولها. كن متأكداً مم استكمال الدورة العلاجية.</p><p><strong>إذا توقفت عن تناول سارف</strong></p><p>من الضرولاياستكمال الدورة العلاجية<strong> </strong>ولو شعرت بالتحسن بعد بضعة أيام. إذا توقفت سريعاً عن تناول هذا الدواء، قد لا تتماثل العدوى للشفاء كليةً أو تتدهور أعراض العدوى. وقد يمكنك أيضاً تطوير المقاومة للمضادات الحيوية.<strong> </strong></p><p><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، قد يؤدي هذا الدواء<strong> </strong>إلى حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص.</p><p><strong>الشائعة </strong></p><p>قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص</p><p>-&nbsp; غثيان، إسهال</p><p>-&nbsp; ألم في المفاصل لدى الأطفال</p><p><strong>غير شائعة </strong></p><p>قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص</p><p>-&nbsp; عدوى فطرية إضافية</p><p>-&nbsp; تركيزات عالية من الخلايا الحمضية، هو نوع من أنواع خلايا الدم البيضاء</p><p>-&nbsp; فقدان الشهية</p><p>-&nbsp; فرط النشاط أو الهياج</p><p>-&nbsp; صداع، دوخة، مشاكل في النوم، أو اضطرابات في التذوق</p><p>-&nbsp; تقيؤ، ألم في البطن، مشاكل في الجهاز الهضمي على سبيل المثال اضطرابات في المعدة (عسر الهضم/حرقة المعدة)، أو ريح.</p><p>-&nbsp; ارتفاع كميات بعض المواد في الدم (ترانس امينز و/أو بيليروبين)</p><p>-&nbsp; طفح جلدي، حكة، أو شرى</p><p>-&nbsp; ألم في المفاصل لدى البالغين</p><p>-&nbsp; ضعف في وظائف الكلى</p><p>-&nbsp; آلام في العضلات و العظام، شعور بالإعياء (الوهن)، أو حمى</p><p>-&nbsp; زيادة فوسفاتاز قلوي في الدم (هي مادة معينة في الدم)</p><p><strong>نادرة </strong></p><p>قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص</p><p>-&nbsp; التهاب الأمعاء (التهاب القولون) المرتبط بتناول المضادات الحيوية (قد تكون مهددة للحياة في حالات نادرة جداً) (انظر القسم 2: تحذيرات واحتياطات)</p><p>-&nbsp; تغيرات في تعداد الدم (قلة الكريات البيض، زيادة الكريات البيض، قلة العدلات، فقر الدم) ارتفاع أو انخفاض كميات عامل التخثر الدموية (الصفائح الدموية)</p><p>-&nbsp; تفاعلات تحسسية، تورم (وذمة)، أو تورم سريع للجلد و الأغشية المخاطية (الوذمة الوعائية)</p><p>-&nbsp; زيادة مستويات سكر الدم</p><p>-&nbsp; انخفاض مستويات سكر الدم (انظر قسم 2: التحذيرات واحتياطات)</p><p>-&nbsp; ارتباك، قلة الوعي، القلق، أحلام غريبة، اكتئاب (مما يؤدي إلى التفكير بالانتحار، محاولات انتحارية، محاولة انتحار كاملة)، أو الهلوسة</p><p>-&nbsp; وخز وخدر، حساسية غير عادية تجاه المحفزات للحواس، قلة تحسس الجلد، ارتعاش، نوبات صرع (انظر قسم 2: تحذيرات واحتياطات)، أو دوخة</p><p>-&nbsp; مشاكل في البصر بما في ذلك ازدواج الرؤية.</p><p>-&nbsp; طنين في &nbsp;الأذنين، فقدان السمع، ضعف السمع</p><p>-&nbsp; تسارع ضربات القلب</p><p>-&nbsp; تمدد الأوعية الدموية، انخفاض ضغط الدم، أو إغماء</p><p>-&nbsp; ضيق في التنفس، بما في ذلك أعراض الربو</p><p>-&nbsp; أمراض الكبد، يرقان (ركود الصفراوي)، أو الالتهاب الكبدي</p><p>-&nbsp; الحساسية تجاه الضوء (انظر قسم 2: تحذيرات واحتياطات)</p><p>-&nbsp; ألم في العضلات، التهاب المفاصل، زيادة التوتر العضلي، أو تشنج</p><p>-&nbsp; فشل الكلى، ظهور دم أو بلورات في البول (انظر قسم 2: تحذيرات واحتياطات)، التهاب الجهاز البولي</p><p>-&nbsp; احتباس السوائل أو فرط التعرق</p><p>-&nbsp; ارتفاع مستويات إنزيم أميلاز</p><p><strong>نادرة جداً </strong></p><p>قد تؤثر على ما يصل إلى شخص واحد من كل 10000 شخص</p><p>-&nbsp; أنواع خاصة من انخفاض عدد خلايا الدم الحمراء (فقر الدم الانحلالي)، انخفاض خطير في نوع من خلايا الدم البيضاء (ندرة المحببات)، انخفاض في عدد الخلايا الحمراء&nbsp; وخلايا الدم البيضاء والصفائح الدموية (قلة الكريات الشاملة)، التي قد تكون مميتة، و تثبيط نقي العظم، التي قد تكون أيضاً مهددة للحياة (انظر قسم 2: تحذيرات واحتياطات)</p><p>-&nbsp; تفاعلات تحسسية شديدة (تفاعلات فرط الحساسية/الصدمة التأقية، التي قد تكون مميتة &ndash; داء المصل) (انظر قسم 2: تحذيرات واحتياطات)</p><p>-&nbsp; اضطرابات عقلية (تفاعلات نفسية مما قد تؤدي إلى تفكير في الانتحار، محاولات انتحارية، أو محاولة انتحار كاملة) (انظر قسم 2: التحذيرات والاحتياطات)</p><p>-&nbsp; الصداع النصفي، اضطراب في التوازن، عدم التوازن في المشي (اضطراب في طريقة المشي)، اضطراب في حاسة الشم، الضغط على الدماغ (الضغط داخل الجمجمة وورم المخي الكاذب)</p><p>-&nbsp; تشوهات باللون البصري</p><p>-&nbsp; التهاب جدار الأوعية الدموية</p><p>-&nbsp; التهاب البنكرياس</p><p>-&nbsp; موت خلايا الكبد (تنخر الكبد) مما يؤدي بصورة نادرة إلى فشل كبدي مهدد للحياة.</p><p>-&nbsp; نزيف صغير بحجم رأس الدبوس تحت الجلد (بقع)، ظهور طفح جلدي متعدد الاشكال (على سبيل المثال متلازمة ستيفن جونسون المهددة للحياة، انحلال البشرة السمي التنخري)</p><p>-&nbsp; ضعف العضلات، التهاب الأوتار، تمزق في الوتر- وبصفة خاصة في الوتر الكبير في الجزء الخلفي من الكاحل (الوتر العقبي) (انظر قسم 2: تحذيرات واحتياطات)، تدهور أعراض الوهن العضي الوبيل (انظر قسم 2: تحذيرات واحتياطات)</p><p><strong>غير معروفة</strong></p><p>لا يمكن تقدير معدل تكرار الحدوث من البيانات المتاحة.</p><p>-&nbsp; الشعور الزائد بالهياج (هوس) أو الشعور بالتفاؤل الزائد و فرط النشاط (هوس خفيف).</p><p>-&nbsp; الاضطرابات المرتبطة بالجهاز العصبي على سبيل المثال ألم، حرقة، وخز، خدر و/أو الشعور بالضعف في الأطراف (الاعتلال العصبي المحيطي و اعتلال الأعصاب)</p><p>-&nbsp; اضطرابات نظم القلب، عدم انتظام ضربات القلب التي تهدد الحياة، تغير في ضربات القلب (تعرف باسم &quot;إطالة فترة كيو تي&quot;، تظهر في التخطيط الكهربائي للقلب، نشاط الكهربائي للقلب)</p><p>-&nbsp; طفح الجلدي المصحوب بظهور بثور</p><p>-&nbsp; فرط الحساسية للتفاعلات الدوائية مع فرط الحمضات والأعراض الجهازية.</p><p>-&nbsp; تأثير على تخثر الدم (لدى المرضى الذين يتلقون العلاج بمثبطات فيتامين ك)</p><p><strong>في </strong><strong>حال</strong> <strong>زيادة حدة أي من التأثيرات الجانبية، أو إذا تعرضت لأية </strong><strong>تأثيرات جانبية أخرى يحتمل حدوثها ولم تذكر في هذه النشرة، يرجى إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong><br /><strong>&nbsp;المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><strong>رقم الفاكس:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>7662-205-11-966+</p><p><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: </strong>2038222-11-966+&nbsp;</p><p><strong>تحويلة هاتف:</strong>2340-2334-2354-2353-2356-2317</p><p><strong>الهاتف المجاني: 8002490000</strong></p><p><strong>البريد الإلكتروني:</strong><strong> </strong><strong>&nbsp;</strong>npc.drug@sfda.gov.sa</p><p><strong>الموقع الإلكتروني: </strong>www.sfda.gov.sa/npc</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p>&middot;&nbsp; لا تتناول هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط.</p><p>&middot;&nbsp; احفظ الدواء في درجة الحرارة أقل من &nbsp;30م&ordm;.</p><p>&middot;&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي السيبروفلوكساسين. كل قرص يحتوي على 250 ملغم، 500 ملغم، أو 750 ملغم من السيبروفلوكساسين (على هيئة هيدروكلوريد).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>المواد غير الفعالة الأخرى: جلايكولات نشا الصوديوم، كروس بوفيدون، بلورات السليلوز المتناهية الصغر، استيارات المغنيسيوم، ايثانول 96 %،&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبروميللوز، بولي إثيلين جلايكول وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر<strong> سارف </strong>250 ملغم و500 ملغم في عبوات تحتوي على 10 &nbsp;و100 قرصاً.</p><p>يتوفر<strong> سارف </strong>750 ملغم في عبوات تحتوي على 10 &nbsp;أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية&quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
15/09/2016

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sarf 750mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:
Item No.	Material Name	Scale (mg /tablet)
		
	Active Ingredients:	
1.		Ciprofloxacin 	750.000
	Use: Ciprofloxacin HCl, H2O	900.000
	(Added 3% as an extra to compensate the moisture)	
		
	Inactive Ingredients:	
1.		Sodium Starch Glycolate (primojel)	118.000
2.		Crospovidone (Kollidone CL)	45.000
3.		Microcrystalline Cellulose (Avicel)	60.000
4.		Magnesium Stearate	7.000
5.		Ethanol 95%*	q.s. *
		
	Coating Materials:	
1.		Hypromellose	18.000
2.		Polyethylene Glycol 4000	6.000
3.		Titanium Dioxide	6.000

* Evaporated during process and does not appear in the final product.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-Coated Tablets
Description: White to off-white, oblong, film coated tablets, may have matt or slightly unsmooth surface.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Sarf</strong> is indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p><strong><u>Adults</u></strong></p><p>&sect; Lower respiratory tract infections due to Gram-negative bacteria</p><p>-&nbsp;&nbsp; exacerbations of chronic obstructive pulmonary disease</p><p>-&nbsp;&nbsp; broncho-pulmonary infections in cystic fibrosis or in bronchiectasis</p><p>-&nbsp;&nbsp; pneumonia</p><p>&sect; Chronic suppurative otitis media</p><p>&sect; Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria</p><p>&sect; Urinary tract infections</p><p>&sect; Genital tract infections</p><p>-&nbsp;&nbsp; gonococcal uretritis and cervicitis due to susceptible&nbsp;<em>Neisseria gonorrhoeae</em></p><p>-&nbsp;&nbsp; epididymo-orchitis including cases due to susceptible&nbsp;<em>Neisseria gonorrhoeae</em></p><p>-&nbsp;&nbsp; pelvic inflammatory disease including cases due to susceptible&nbsp;<em>Neisseria gonorrhoeae</em></p><p>&sect; Infections of the gastro-intestinal tract (e.g. travellers&#39; diarrhoea)</p><p>&sect; Intra-abdominal infections</p><p>&sect; Infections of the skin and soft tissue caused by Gram-negative bacteria</p><p>&sect; Malignant external otitis</p><p>&sect; Infections of the bones and joints</p><p>&sect; Prophylaxis of invasive infections due to&nbsp;<em>Neisseria meningitidis</em></p><p>&sect; Inhalation anthrax (post-exposure prophylaxis and curative treatment)</p><p>Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p><strong><u>Children and adolescents</u></strong></p><p>&sect; Broncho-pulmonary infections in cystic fibrosis caused by&nbsp;<em>Pseudomonas aeruginosa</em></p><p>&sect; Complicated urinary tract infections and pyelonephritis</p><p>&sect; Inhalation anthrax (post-exposure prophylaxis and curative treatment)</p><p>Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered to be necessary.</p><p>Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.</p><p>The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.</p><p>Treatment of infections due to certain bacteria (e.g.&nbsp;<em>Pseudomonas aeruginosa</em>,&nbsp;<em>Acinetobacter&nbsp;</em>or&nbsp;<em>Staphylococci)</em>&nbsp;may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.</p><p><strong><em><u>Adults</u></em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:713px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the lower respiratory tract</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections of the upper respiratory tract</p></td><td style="vertical-align:top"><p>Acute exacerbation of chronic sinusitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Malignant external otitis</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td><td style="vertical-align:top"><p>28 days up to 3 months</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Urinary tract infections (see section 4.4)</p></td><td rowspan="2" style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250 mg twice daily to 500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>In pre-menopausal women, 500 mg single dose may be used</p></td></tr><tr><td style="vertical-align:top"><p>Complicated cystitis, Uncomplicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Complicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Prostatitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>2 to 4 weeks (acute) to 4 to 6 weeks (chronic)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Genital tract infections</p></td><td style="vertical-align:top"><p>Gonococcal uretritis and cervicitis</p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Epididymo-orchitis and pelvic inflammatory diseases</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 14 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Infections of the gastro-intestinal tract and intra-abdominal infections</p></td><td style="vertical-align:top"><p>Diarrhoea caused by bacterial pathogens including<em>Shigella&nbsp;</em>spp. other than<em>Shigella dysenteriae</em>&nbsp;type 1 and empirical treatment of severe travellers&#39; diarrhoea</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>1 day</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by<em>Shigella dysenteriae</em>&nbsp;type 1</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>5 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by&nbsp;<em>Vibrio cholerae</em></p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Typhoid fever</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections due to Gram-negative bacteria</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>5 to 14 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the skin and soft tissue</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bone and joint infections</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>max. of 3 months</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance.</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>Therapy should be continued over the entire period of neutropenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prophylaxis of invasive infections due to&nbsp;<em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate.</p><p>Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>60 days from the confirmation of&nbsp;<em>Bacillus anthracis</em>&nbsp;exposure</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><strong><em><u>Paediatric population</u></em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:715px"><tbody><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cystic fibrosis</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections and pyelonephritis</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 21 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose.</p></td><td style="vertical-align:top"><p>60 days from the confirmation of&nbsp;<em>Bacillus anthracis</em>&nbsp;exposure</p></td></tr><tr><td style="vertical-align:top"><p>Other severe infections</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>According to the type of infections</p></td></tr></tbody></table><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Elderly patients</u></em></strong></p><p>Elderly patients should receive a dose selected according to the severity of the infection and the patient&#39;s creatinine clearance.</p><p><strong><em><u>Patients with renal and hepatic impairment</u></em></strong></p><p>Recommended starting and maintenance doses for patients with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:715px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance</strong></p><p><strong>[mL/min/1.73 m<sup>2</sup>]</strong></p></td><td style="vertical-align:top"><p><strong>Serum Creatinine</strong></p><p><strong>[&micro;mol/L]</strong></p></td><td style="vertical-align:top"><p><strong>Oral Dose</strong></p><p><strong>[mg]</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 60</p></td><td style="vertical-align:top"><p>&lt; 124</p></td><td style="vertical-align:top"><p>See Usual Dosage.</p></td></tr><tr><td style="vertical-align:top"><p>30-60</p></td><td style="vertical-align:top"><p>124 to 168</p></td><td style="vertical-align:top"><p>250-500 mg every 12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr><tr><td style="vertical-align:top"><p>Patients on haemodialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h (after dialysis)</p></td></tr><tr><td style="vertical-align:top"><p>Patients on peritoneal dialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr></tbody></table><p>In patients with impaired liver function no dose adjustment is required.</p><p>Dosing in children with impaired renal and/or hepatic function has not been studied.</p><p><strong><u>Method of administration</u></strong></p><p>Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If taken on an empty stomach, the active substance is absorbed more rapidly. Ciprofloxacin tablets should not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit-juice (e.g. calcium-fortified orange juice) (see section 4.5).</p><p>In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1.
	Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Severe infections and mixed infections with Gram-positive and anaerobic pathogens</u></strong></p><p>Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.</p><p><strong><u>Streptococcal Infections (including Streptococcus pneumoniae)</u></strong></p><p>Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy<em>.</em></p><p><strong><u>Genital tract infections</u></strong></p><p>Gonococcal uretritis, cervicitis, epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;isolates.</p><p>Therefore, ciprofloxacin should be administered for the treatment of gonococcal uretritis or cervicitis only if ciprofloxacin-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;can be excluded.</p><p>For epididymo-orchitis and pelvic inflammatory diseases, empirical ciprofloxacin should only be considered in combination with another appropriate antibacterial agent (e.g. a cephalosporin) unless ciprofloxacin-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><strong><u>Urinary tract infections</u></strong></p><p>Resistance to fluoroquinolones of&nbsp;<em>Escherichia coli&nbsp;</em>&ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in&nbsp;<em>Escherichia coli</em>&nbsp;to fluoroquinolones.</p><p>The single dose of ciprofloxacin that may be used in uncomplicated cystitis in pre-menopausal women is expected to be associated with lower efficacy than the longer treatment duration. This is all the more to be taken into account as regards the increasing resistance level of&nbsp;<em>Escherichia coli</em>&nbsp;to quinolones.</p><p><strong><u>Intra-abdominal infections</u></strong></p><p>There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.</p><p><strong><u>Travellers&#39; diarrhoea</u></strong></p><p>The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.</p><p><strong><u>Infections of the bones and joints</u></strong></p><p>Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.</p><p><strong><u>Inhalational anthrax</u></strong></p><p>Use in humans is based on&nbsp;<em>in-vitro</em>&nbsp;susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><strong><u>Paediatric population</u></strong></p><p>The use of ciprofloxacin in children and adolescents should follow available official guidance. Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.</p><p>Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue.</p><p><strong><em>Broncho-pulmonary infections in cystic fibrosis</em></strong></p><p>Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age.</p><p><strong><em>Complicated urinary tract infections and pyelonephritis</em></strong></p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.</p><p>Clinical trials have included children and adolescents aged 1-17 years.</p><p><strong><em>Other specific severe infections</em></strong></p><p>Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use</p><p>The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.</p><p><strong><u>Hypersensitivity</u></strong></p><p>Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose (see section 4.8) and may be life-threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.</p><p><strong><u>Musculoskeletal System</u></strong></p><p>Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.</p><p>Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, even within the first 48 hours of treatment. Inflammation and ruptures of tendon may occur even up to several months after discontinuation of ciprofloxacin therapy. The risk of tendinopathy may be increased in elderly patients or in patients concomitantly treated with corticosteroids (see section 4.8).</p><p>At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued. Care should be taken to keep the affected limb at rest.</p><p>Ciprofloxacin should be used with caution in patients with myasthenia gravis, because symptoms can be exacerbated (see section 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Vision disorders</u></strong></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately</p><p><strong><u>Photosensitivity</u></strong></p><p>Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).</p><p><strong><u>Central Nervous System</u></strong></p><p>Ciprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued (see section 4.8). Psychiatric reactions may occur even after first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to suicidal ideations/thoughts culminating in attempted suicide or completed suicide. In the occurrence of such cases, ciprofloxacin should be discontinued.</p><p>Cases of polyneuropathy (based on neurological symptoms such as pain, burning, sensory disturbances or muscle weakness, alone or in combination) have been reported in patients receiving ciprofloxacin. Ciprofloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain, burning, tingling, numbness, and/or weakness in order to prevent the development of an irreversible condition (see section 4.8).</p><p><strong><u>Cardiac disorders</u></strong></p><p>Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>&sect; congenital long QT syndrome</p><p>&sect; concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics)</p><p>&sect; uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)</p><p>&sect; cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations.</p><p>(See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).</p><p><strong><u>Hypoglycemia</u></strong></p><p>As with other quinolones, hypoglycemia has been reported most often in diabetic patients, predominantly in the elderly population. In all diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p><strong><u>Gastrointestinal System</u></strong></p><p>The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.</p><p><strong><u>Renal and urinary system</u></strong></p><p>Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.</p><p><strong><u>Impaired renal function</u></strong></p><p>Since ciprofloxacin is largely excreted unchanged via renal pathway dose adjustment is needed in patients with impaired renal function as described in section 4.2 to avoid an increase in adverse drug reactions due to accumulation of ciprofloxacin.</p><p><strong><u>Hepatobiliary system</u></strong></p><p>Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.</p><p><strong><u>Glucose-6-phosphate dehydrogenase deficiency</u></strong></p><p>Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of haemolysis should be monitored.</p><p><strong><u>Resistance</u></strong></p><p>During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by&nbsp;<em>Staphylococcus</em>&nbsp;and&nbsp;<em>Pseudomonas</em>&nbsp;species.</p><p><strong><u>Cytochrome P450</u></strong></p><p>Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, olanzapine, ropinirole, tizanidine, duloxetine). Co-administration of ciprofloxacin and tizanidine is contra-indicated. Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5).</p><p><strong><u>Methotrexate</u></strong></p><p>The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).</p><p><strong><u>Interaction with tests</u></strong></p><p>The&nbsp;<em>in-vitro</em>&nbsp;activity of ciprofloxacin against&nbsp;<em>Mycobacterium tuberculosis</em>&nbsp;might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Effects of other products on ciprofloxacin</u></strong></p><p><em><u>Drugs known to prolong QT interval</u></em></p><p>Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4).</p><p><em><u>Chelation Complex Formation</u></em></p><p>The simultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer or lanthanum carbonate), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin. Consequently, ciprofloxacin should be administered either 1-2 hours before or at least 4 hours after these preparations. The restriction does not apply to antacids belonging to the class of H2 receptor blockers.</p><p><em><u>Food and Dairy Products</u></em></p><p>Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.</p><p><em><u>Probenecid</u></em></p><p>Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.</p><p><em><u>Metoclopramide</u></em></p><p>Metoclopramide accelerates the absorption of ciprofloxacin (oral) resulting in a shorter time to reach maximum plasma concentrations. No effect was seen on the bioavailability of ciprofloxacin.</p><p><em><u>Omeprazole</u></em></p><p>Concomitant administration of ciprofloxacin and omeprazole containing medicinal products results in a slight reduction of C<sub>max</sub>&nbsp;and AUC of ciprofloxacin.</p><p><strong><u>Effects of ciprofloxacin on other medicinal products</u></strong></p><p><em><u>Tizanidine</u></em></p><p>Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (C<sub>max</sub>&nbsp;increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.</p><p><em><u>Methotrexate</u></em></p><p>Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).</p><p><em><u>Theophylline</u></em></p><p>Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary (see section 4.4).</p><p><em><u>Other xanthine derivatives</u></em></p><p>On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.</p><p><em><u>Phenytoin</u></em></p><p>Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.</p><p><em><u>Cyclosporin</u></em></p><p>A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.</p><p><em><u>Vitamin K antagonists</u></em></p><p>Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalised ratio) is difficult to assess. The INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol, phenprocoumon, or fluindione).</p><p><em><u>Duloxetine</u></em></p><p>In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and C<sub>max</sub>&nbsp;of duloxetine. Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be expected upon concomitant administration (see section 4.4).</p><p><em><u>Ropinirole</u></em></p><p>It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of C<sub>max</sub>&nbsp;and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin (see section 4.4).</p><p><em><u>Lidocaine</u></em></p><p>It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction with ciprofloxacin associated with side effects may occur upon concomitant administration.</p><p><em><u>Clozapine</u></em></p><p>Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised (see section 4.4).</p><p><em><u>Sildenafil</u></em></p><p>C<sub>max</sub>&nbsp;and AUC of sildenafil were increased approximately twofold in healthy subjects after an oral dose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.</p><p><strong><u>Breast-feeding</u></strong></p><p>Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.</p><p>ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin (oral, intravenous, and sequential therapy) sorted by categories of frequencies is listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:750px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&ge; 1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&ge; 1/1,000 to &lt; 1/100</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>&ge; 1/10,000 to &lt; 1/1,000</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>&lt; 1/10,000</p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p><p>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mycotic superinfections</p></td><td style="vertical-align:top"><p>Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Anaemia</p><p>Neutropenia</p><p>Leukocytosis</p><p>Thrombocytopenia</p><p>Thrombocytaemia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia</p><p>Agranulocytosis</p><p>Pancytopenia (life-threatening)</p><p>Bone marrow depression (life-threatening)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction</p><p>Allergic oedema / angiooedema</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Anaphylactic shock (life-threatening) (see section 4.4)</p><p>Serum sickness-like reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypoglycaemia (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Psychomotor hyperactivity / agitation</p></td><td style="vertical-align:top"><p>Confusion and disorientation</p><p>Anxiety reaction</p><p>Abnormal dreams</p><p>Depression</p><p>(potentially culminating in suicidal ideations/thoughts or suicide attempts and completed suicide) (see section 4.4)</p><p>Hallucinations</p></td><td style="vertical-align:top"><p>Psychotic reactions</p><p>(potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide)</p><p>(see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p><p>Sleep disorders</p><p>Taste disorders</p></td><td style="vertical-align:top"><p>Par- and Dysaesthesia</p><p>Hypoaesthesia</p><p>Tremor</p><p>Seizures (including status epilepticus see section 4.4)</p><p>Vertigo</p></td><td style="vertical-align:top"><p>Migraine</p><p>Disturbed coordination</p><p>Gait disturbance</p><p>Olfactory nerve disorders</p><p>Intracranial hypertension and pseudotumor cerebri</p></td><td style="vertical-align:top"><p>Peripheral neuropathy and polyneur-opathy</p><p>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances (e.g. diplopia)</p></td><td style="vertical-align:top"><p>Visual colour distortions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing loss / Hearing impaired</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ventricular arrhythmia, and torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see sections 4.4 and 4.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p><p>Hypotension</p><p>Syncope</p></td><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea (including asthmatic condition)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Gastrointestinal and abdominal pains</p><p>Dyspepsia</p><p>Flatulence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase in transaminases</p><p>Increased bilirubin</p></td><td style="vertical-align:top"><p>Hepatic impairment</p><p>Cholestatic icterus</p><p>Hepatitis</p></td><td style="vertical-align:top"><p>Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Photosensitivity reactions (see section 4.4)</p></td><td style="vertical-align:top"><p>Petechiae</p><p>Erythema multiforme</p><p>Erythema nodosum</p><p>Stevens-Johnson syndrome (potentially life-threatening)</p><p>Toxic epidermal necrolysis (potentially life-threatening)</p></td><td style="vertical-align:top"><p>Acute generalised exanthematous pustulosis (AGEP)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculo-skeletal and Connective Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Musculoskeletal pain (e.g. extremity pain, back pain, chest pain)</p><p>Arthralgia</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Arthritis</p><p>Increased muscle tone and cramping</p></td><td style="vertical-align:top"><p>Muscular weakness</p><p>Tendinitis</p><p>Tendon rupture (predominantly Achilles tendon) (see section 4.4)</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal impairment</p></td><td style="vertical-align:top"><p>Renal failure</p><p>Haematuria</p><p>Crystalluria (see section 4.4)</p><p>Tubulointerstitial nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia</p><p>Fever</p></td><td style="vertical-align:top"><p>Oedema</p><p>Sweating (hyperhidrosis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Increased amylase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>International normalised ratio increased (in patients treated with Vitamin K antagonists)</p></td></tr></tbody></table><p><strong><u>Paediatric population</u></strong></p><p>The incidence of arthropathy, mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><strong><em><u>To report any side effect(s)</u></em></strong><strong><em><u>:</u></em></strong><strong><em><u> </u></em></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.</p><p>Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.</p><p>Apart from routine emergency measures, e.g. ventricular emptying followed by medical carbon it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystalluria. Patients should be kept well hydrated. Calcium or magnesium containing antacids may theoretically reduce the absorption of ciprofloxacin in overdoses</p><p>Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Fluoroquinolones, ATC code: J01MA02</p><p><strong><u>Mechanism of action</u></strong></p><p>As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.</p><p><strong><u>Pharmacokinetic/pharmacodynamic relationship</u></strong></p><p>Efficacy mainly depends on the relation between the maximum concentration in serum (C<sub>max</sub>) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.</p><p><strong><u>Mechanism of resistance:</u></strong></p><p><em>In-vitro&nbsp;</em>resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.</p><p>Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All&nbsp;<em>in-vitro&nbsp;</em>mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in<em>Pseudomonas aeruginosa)&nbsp;</em>and efflux mechanisms may affect susceptibility to ciprofloxacin<em>.</em></p><p>Plasmid-mediated resistance encoded by qnr-genes has been reported.</p><p><strong><u>Spectrum of antibacterial activity</u></strong></p><p>Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:</p><p><strong><em><u>EUCAST Recommendations</u></em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:700px"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganisms</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>S &le; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas&nbsp;</em>spp</p></td><td style="vertical-align:top"><p>S &le; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter&nbsp;</em>spp</p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus&nbsp;</em>spp.<sup>1</sup></p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em>&nbsp;and&nbsp;<em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>S &le; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species-related breakpoints<strong>*</strong></p></td><td style="vertical-align:top"><p>S &le; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr></tbody></table><p>1&nbsp;<em>Staphylococcus</em>&nbsp;spp. - breakpoints for ciprofloxacin relate to high dose therapy.</p><p>* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable</p><p>Groupings of relevant species according to ciprofloxacin susceptibility (for&nbsp;<em>Streptococcus</em>&nbsp;species see section 4.4)</p><table border="1" cellspacing="0" cellpadding="0" style="width:700px"><tbody><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Bacillus anthracis&nbsp;</em>(1)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Aeromonas&nbsp;</em>spp.</p><p><em>Brucella&nbsp;</em>spp.</p><p><em>Citrobacter koseri</em></p><p><em>Francisella tularensis</em></p><p><em>Haemophilus ducreyi</em></p><p><em>Haemophilus influenzae*</em></p><p><em>Legionella&nbsp;</em>spp.</p><p><em>Moraxella catarrhalis*</em></p><p><em>Neisseria meningitidis</em></p><p><em>Pasteurella&nbsp;</em>spp.</p><p><em>Salmonella&nbsp;</em>spp.<em>*</em></p><p><em>Shigella&nbsp;</em>spp.<em>*</em></p><p><em>Vibrio&nbsp;</em>spp.</p><p><em>Yersinia pestis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Mobiluncus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Chlamydia trachomatis</em>&nbsp;($)</p><p><em>Chlamydia pneumoniae</em>&nbsp;($)</p><p><em>Mycoplasma hominis&nbsp;</em>($)</p><p><em>Mycoplasma pneumoniae</em>&nbsp;($)</p></td></tr><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis</em>&nbsp;($)</p><p><em>Staphylococcus&nbsp;</em>spp. *(2)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter baumannii<sup>+</sup></em></p><p><em>Burkholderia cepacia<sup>+</sup>*</em></p><p><em>Campylobacter&nbsp;</em>spp.<em><sup>+</sup>*</em></p><p><em>Citrobacter freundii*</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae*</em></p><p><em>Escherichia coli*</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae*</em></p><p><em>Morganella morganii*</em></p><p><em>Neisseria gonorrhoeae*</em></p><p><em>Proteus mirabilis*</em></p><p><em>Proteus vulgaris*</em></p><p><em>Providencia&nbsp;</em>spp.</p><p><em>Pseudomonas aeruginosa*</em></p><p><em>Pseudomonas fluorescens</em></p><p><em>Serratia marcescens*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Peptostreptococcus&nbsp;</em>spp.</p><p><em>Propionibacterium acnes</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>INHERENTLY RESISTANT ORGANISMS</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Actinomyces</em></p><p><em>Enteroccus faecium</em></p><p><em>Listeria monocytogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Excepted as listed above</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Mycoplasma genitalium</em></p><p><em>Ureaplasma urealitycum</em></p></td></tr><tr><td style="vertical-align:top"><p>* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications</p><p><sup>+&nbsp;</sup>Resistance rate &ge; 50% in one or more EU countries</p><p>($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance</p><p>(1): Studies have been conducted in experimental animal infections due to inhalations of&nbsp;<em>Bacillus anthracis</em>&nbsp;spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on&nbsp;<em>in-vitro</em>&nbsp;susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.</p><p>(2): Methicillin-resistant&nbsp;<em>S. aureus</em>&nbsp;very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.</p><p>Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (C<sub>max</sub>) between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.</p><p>The absolute bioavailability is approximately 70-80%.</p><p>A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.</p><p><strong><u>Distribution</u></strong></p><p>Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a non-ionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.</p><p><strong><u>Biotransformation</u></strong></p><p>Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4). The metabolites display&nbsp;<em>in-vitro</em>antimicrobial activity but to a lower degree than the parent compound.</p><p>Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.</p><p><strong><u>Elimination</u></strong></p><p>Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.</p><table border="1" cellspacing="0" cellpadding="0" style="width:708px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Excretion of ciprofloxacin (% of dose)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Oral Administration</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Urine</strong></p></td><td style="vertical-align:top"><p><strong>Faeces</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>44.7</p></td><td style="vertical-align:top"><p>25.0</p></td></tr><tr><td style="vertical-align:top"><p>Metabolites (M<sub>1</sub>-M<sub>4</sub>)</p></td><td style="vertical-align:top"><p>11.3</p></td><td style="vertical-align:top"><p>7.5</p></td></tr></tbody></table><p>Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.</p><p>Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.</p><p><strong><u>Paediatric patients</u></strong></p><p>The pharmacokinetic data in paediatric patients are limited.</p><p>In a study in children C<sub>max</sub>&nbsp;and AUC were not age-dependent (above one year of age). No notable increase in C<sub>max</sub>&nbsp;and AUC upon multiple dosing (10 mg/kg three times daily) was observed.</p><p>In 10 children with severe sepsis C<sub>max</sub>&nbsp;was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.</p><p>These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.</p><p>Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin&nbsp;<em>in-vitro</em>and in animal experiments. This effect was comparable to that of other gyrase inhibitors.</p><p><strong><u>Articular tolerability</u></strong></p><p>As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" align="left" style="width:706px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium Starch Glycolate (primojel)</p></td></tr><tr><td><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crospovidone (Kollidone CL)</p></td></tr><tr><td><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline Cellulose (Avicel)</p></td></tr><tr><td><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium Stearate</p></td></tr><tr><td><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ethanol 95%*</p></td></tr><tr><td><p><strong><u>&nbsp;</u></strong></p></td></tr><tr><td><p><strong><u>Coating Materials:</u></strong></p></td></tr><tr><td><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose</p></td></tr><tr><td><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polyethylene Glycol 4000</p></td></tr><tr><td><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Titanium Dioxide</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>* Evaporated during process and does not appear in the final product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C. 6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1x10&#39;s tablets in an aluminium-PVC blister strip, packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12. May. 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>